BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sabbatino F, Conti V, Franci G, Sellitto C, Manzo V, Pagliano P, De Bellis E, Masullo A, Salzano FA, Caputo A, Peluso I, Zeppa P, Scognamiglio G, Greco G, Zannella C, Ciccarelli M, Cicala C, Vecchione C, Filippelli A, Pepe S. PD-L1 Dysregulation in COVID-19 Patients. Front Immunol 2021;12:695242. [PMID: 34163490 DOI: 10.3389/fimmu.2021.695242] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
Number Citing Articles
1 Bonam SR, Chauvin C, Levillayer L, Mathew MJ, Sakuntabhai A, Bayry J. SARS-CoV-2 Induces Cytokine Responses in Human Basophils. Front Immunol 2022;13:838448. [PMID: 35280992 DOI: 10.3389/fimmu.2022.838448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Aygun H. Vitamin D can reduce severity in COVID-19 through regulation of PD-L1. Naunyn Schmiedebergs Arch Pharmacol 2022;395:487-94. [PMID: 35099571 DOI: 10.1007/s00210-022-02210-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Al-Nesf MAY, Abdesselem HB, Bensmail I, Ibrahim S, Saeed WAH, Mohammed SSI, Razok A, Alhussain H, Aly RMA, Al Maslamani M, Ouararhni K, Khatib MY, Hssain AA, Omrani AS, Al-Kaabi S, Al Khal A, Al-Thani AA, Samsam W, Farooq A, Al-Suwaidi J, Al-Maadheed M, Al-Siddiqi HH, Butler AE, Decock JV, Mohamed-Ali V, Al-Ejeh F. Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nat Commun 2022;13:946. [PMID: 35177642 DOI: 10.1038/s41467-022-28639-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hsieh WC, Lai EY, Liu YT, Wang YF, Tzeng YS, Cui L, Lai YJ, Huang HC, Huang JH, Ni HC, Tsai DY, Liang JJ, Liao CC, Lu YT, Jiang L, Liu MT, Wang JT, Chang SY, Chen CY, Tsai HC, Chang YM, Wernig G, Li CW, Lin KI, Lin YL, Tsai HK, Huang YT, Chen SY. NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. J Clin Invest 2021;131:e146408. [PMID: 34720095 DOI: 10.1172/JCI146408] [Reference Citation Analysis]
5 Mazzoni A, Salvati L, Maggi L, Annunziato F, Cosmi L. Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. Semin Immunol 2021;:101508. [PMID: 34728121 DOI: 10.1016/j.smim.2021.101508] [Reference Citation Analysis]
6 Dąbrowska E, Galińska-Skok B, Waszkiewicz N. Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19. Life (Basel) 2021;11:1056. [PMID: 34685427 DOI: 10.3390/life11101056] [Reference Citation Analysis]
7 Schwab N, Nienhold R, Henkel M, Baschong A, Graber A, Frank A, Mensah N, Koike J, Hernach C, Sachs M, Daun T, Zsikla V, Willi N, Junt T, Mertz KD. COVID-19 Autopsies Reveal Underreporting of SARS-CoV-2 Infection and Scarcity of Co-infections. Front Med 2022;9:868954. [DOI: 10.3389/fmed.2022.868954] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bonam SR, Chauvin C, Mathew MJ, Bayry J. IFN-γ Induces PD-L1 Expression in Primed Human Basophils. Cells 2022;11:801. [DOI: 10.3390/cells11050801] [Reference Citation Analysis]
9 Spuch C, López-garcía M, Rivera-baltanás T, Cabrera-alvargonzález JJ, Gadh S, Rodrigues-amorim D, Álvarez-estévez T, Mora A, Iglesias-martínez-almeida M, Freiría-martínez L, Pérez-rodríguez M, Pérez-gonzález A, López-domínguez A, Longueira-suarez MR, Sousa-domínguez A, Araújo-ameijeiras A, Mosquera-rodríguez D, Crespo M, Vila-fernández D, Regueiro B, Olivares JM. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. Front Pharmacol 2022;13:850583. [DOI: 10.3389/fphar.2022.850583] [Reference Citation Analysis]
10 Moga E, Lynton-pons E, Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Front Immunol 2022;13:904686. [DOI: 10.3389/fimmu.2022.904686] [Reference Citation Analysis]
11 Rutkowska E, Kwiecień I, Kłos K, Rzepecki P, Chciałowski A. Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection. Viruses 2022;14:819. [PMID: 35458548 DOI: 10.3390/v14040819] [Reference Citation Analysis]
12 Chavez-galan L, Ruiz A, Martinez-espinosa K, Aguilar-duran H, Torres M, Falfan-valencia R, Pérez-rubio G, Selman M, Buendia-roldan I. Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation. Biomolecules 2022;12:445. [DOI: 10.3390/biom12030445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zavvar M, Yahyapoor A, Baghdadi H, Zargaran S, Assadiasl S, Abdolmohammadi K, Hossein Abooei A, Reza Sattarian M, Jalalifarahani M, Zarei N, Farahvash A, Fatahi Y, Deniz G, Zarebavani M, Nicknam MH. COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches. International Immunopharmacology 2022;107:108655. [DOI: 10.1016/j.intimp.2022.108655] [Reference Citation Analysis]
14 Morrell ED, Bhatraju PK, Sathe NA, Lawson J, Mabrey L, Holton SE, Presnell SR, Wiedeman A, Acosta-Vega C, Mitchem MA, Liu T, Chai XY, Sahi S, Brager C, Orlov M, Sakr SS, Sader A, Lum DM, Koetje N, Garay A, Barnes E, Cromer G, Bray MK, Pipavath S, Fink SL, Evans L, Long SA, West TE, Wurfel MM, Mikacenic C. Chemokines, Soluble PD-L1, and Immune Cell Hyporesponsiveness are Distinct Features of SARS-CoV-2 Critical Illness. Am J Physiol Lung Cell Mol Physiol 2022. [PMID: 35608267 DOI: 10.1152/ajplung.00049.2022] [Reference Citation Analysis]
15 Erol A. Importance of Efferocytosis in COVID-19 Mortality. IDR 2022;Volume 15:995-1007. [DOI: 10.2147/idr.s348639] [Reference Citation Analysis]
16 Zhao M, Tian C, Cong S, Di X, Wang K. From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases? Front Immunol 2022;13:877303. [DOI: 10.3389/fimmu.2022.877303] [Reference Citation Analysis]
17 Chua TH, Punjabi LS, Khor LY. Tissue Pathogens and Cancers: A Review of Commonly Seen Manifestations in Histo- and Cytopathology. Pathogens 2021;10:1410. [PMID: 34832566 DOI: 10.3390/pathogens10111410] [Reference Citation Analysis]
18 Zhang S, Amahong K, Zhang C, Li F, Gao J, Qiu Y, Zhu F. RNA-RNA interactions between SARS-CoV-2 and host benefit viral development and evolution during COVID-19 infection. Brief Bioinform 2021:bbab397. [PMID: 34585235 DOI: 10.1093/bib/bbab397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Al-Mterin MA, Alsalman A, Elkord E. Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients. Front Immunol 2022;13:870283. [PMID: 35432324 DOI: 10.3389/fimmu.2022.870283] [Reference Citation Analysis]
20 Rayati Damavandi A, Zolfaghari Baghbadorani P, Kardideh B, Fouladseresht H, Golabi M, Ghezelbash B, Andalib S, Eskandari N, Mirniam SM, Fathi F. The Association of Programmed Death 1 Gene Polymorphisms of PD1.3 G/A and PD1.5 C/T with Risk of COVID-19 in an Iranian Population: A Case-Control Study. Viral Immunol 2022. [PMID: 35512734 DOI: 10.1089/vim.2022.0030] [Reference Citation Analysis]